Airborne microorganisms play a significant role in the transmission of infectious diseases. As such, improving indoor microbial air quality can enhance infection control in numerous settings. This study examined the efficacy of the PlasmaShield® air purification device to remove airborne microorganisms under laboratory conditions. Pure cultures of model microorganisms at varying concentrations were aerosolized using a 1-jet Collison nebulizer through stainless-steel removable piping prior to reaching the PlasmaShield® device. The surviving microorganisms were captured using the Staplex® MBS-6 Six Stage Microbial Air Sampler and enumerated via culture on agar plates. The positive-hole-corrected colony/plaque-forming units were compared with the negative control (microorganisms aerosolized through an empty PlasmaShield® casing). The PlasmaShield® statistically significantly (p < 0.05) reduced airborne Escherichia coli, Staphylococcus epidermidis, Bacteriophage MS2 and Cladosporium sp. compared with the negative control. The maximum removal achieved was estimated to be 4 × log10E. coli (99.99% removal), 4 × log10S. epidermidis (99.97% removal), 7 × log10 MS2 (99.99998% removal) and 5 × log10Cladosporium sp. (99.999% removal). Scanning electron microscope images of the surviving microorganisms showed that the PlasmaShield® damaged the cell membrane of these model microorganisms. This study provides proof-of-concept evidence to support the use of this technology to improve indoor microbial air quality.
26 October 2016 in Sri Lankan Journal of Infectious Diseases
Rapid distinguishing of mycobacterial species and knowledge about their susceptibility is vital for the management of patients with pulmonary disease who are not responding to initial treatment as the mycobacteria have a spectrum of virulence and different susceptibilities to antibiotics. Most biochemical techniques used for species differentiation are laborious and time consuming. Hence molecular techniques are becoming an alternative to existing conventional testing. This study demonstrates the utility of molecular diagnostics for patients with mycobacterial infections who are not responding to initial anti TB therapy.